This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Concordia Healthcare Corp.
Drug Names(s): Riluzole
Description: The mode of action of Rilutek is unknown. Its pharmacological properties include the following, some of which may be related to its effect:
- an inhibitory effect on glutamate release,
- inactivation of voltage-dependent sodium channels, and
- ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
Sanofi and Covis
In April 2013, Covis Pharma Sarl announced an agreement with Sanofi-Aventis to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride), and Kayexalate (sodium polystyrene sulfate) in the United States. Sanofi will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed. Covis Pharma will promote these branded products through its US-based distributor, Covis Pharmaceuticals Inc. Sanofi will manufacture and supply the products for Covis Pharma. The agreement has received Hart-Scott-Rodino regulatory clearance in the United States.
Covis and Concordia
In March 2015, Concordia Healthcare announced it has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis Pharma S..r.l and Covis Injectables, S..r.l for...See full deal structure in Biomedtracker
Pink Sheet In Brief: Rhone-Poulenc Rorer's Rilutek
Additional information available to subscribers only: